38972-95-1

Usage

Uses

Used in Pharmaceutical Industry:
Z-ILE-LEU-OH is used as a therapeutic agent for bone-related diseases such as osteoporosis and osteoarthritis. It serves to inhibit bone resorption by blocking the activity of cathepsin K, thereby helping to maintain or improve bone density.
Used in Biochemical Research:
In the field of biochemical research, Z-ILE-LEU-OH is used as a protease inhibitor to study the role of cathepsin K in bone metabolism and to explore its potential applications in the development of drugs targeting bone disorders.
Used in Drug Development:
Z-ILE-LEU-OH is utilized in drug development as a lead compound for the creation of new therapeutics aimed at treating bone-related diseases by targeting the enzyme cathepsin K and its effects on bone resorption.

InChI:InChI=1/C20H30N2O5/c1-5-14(4)17(18(23)21-16(19(24)25)11-13(2)3)22-20(26)27-12-15-9-7-6-8-10-15/h6-10,13-14,16-17H,5,11-12H2,1-4H3,(H,21,23)(H,22,26)(H,24,25)

Upstream product

• 2666-93-5 (S)-Leu-OMe 
• 88962-32-7 N-Benzyloxycarbonyl-L-isoleucyl-L-leucin-2-bromethylester 
• 88962-23-6 Leucin-2-bromethylester-hydrochlorid 
• 61-90-5 L-leucine 
• 88962-43-0 N-Benzyloxycarbonyl-L-isoleucyl-L-leucin-2-iodethylester 
• 4818-03-5 Z-L-Ile-L-Leu-OMe 
• 3160-59-6 N-Cbz-L-Isoleucine 

Downstream Products

• 438202-62-1 4-((1S,2S)-1-{(S)-1-[3-Cyano-1-(2,2-difluoro-ethyl)-2-oxo-3-(triphenyl-λ⁵-phosphanylidene)-propylcarbamoyl]-3-methyl-butylcarbamoyl}-2-methyl-butylcarbamoyloxymethyl)-benzoic acid methyl ester 
• 438202-56-3 (2S,3S)-2-Amino-3-methyl-pentanoic acid {(S)-1-[3-cyano-1-(2,2-difluoro-ethyl)-2-oxo-3-(triphenyl-λ⁵-phosphanylidene)-propylcarbamoyl]-3-methyl-butyl}-amide 
• 438202-43-8 4-{(1S,2S)-1-[(S)-1-((S)-3,3-Difluoro-1-oxalyl-propylcarbamoyl)-3-methyl-butylcarbamoyl]-2-methyl-butylcarbamoyloxymethyl}-benzoic acid methyl ester 
• 252357-49-6 ((1S,2S)-1-{(S)-1-[3-Cyano-1-(2,2-difluoro-ethyl)-2-oxo-3-(triphenyl-λ⁵-phosphanylidene)-propylcarbamoyl]-3-methyl-butylcarbamoyl}-2-methyl-butyl)-carbamic acid benzyl ester 
• 438202-67-6 {(1S,2S)-1-[(S)-1-(3,3-Difluoro-1-{hydroxy-[1-(4-methoxy-benzyl)-1H-tetrazol-5-yl]-methyl}-propylcarbamoyl)-3-methyl-butylcarbamoyl]-2-methyl-butyl}-carbamic acid benzyl ester 
• 438202-63-2 3-[(S)-2-((2S,3S)-2-Benzyloxycarbonylamino-3-methyl-pentanoylamino)-4-methyl-pentanoylamino]-5,5-difluoro-2-hydroxy-pentanoic acid methyl ester 
• 438202-65-4 3-[(S)-2-((2S,3S)-2-Benzyloxycarbonylamino-3-methyl-pentanoylamino)-4-methyl-pentanoylamino]-5,5-difluoro-pentanoic acid methyl ester 
• 26462-22-6 Ile-Leu 

Relevant academic research and scientific papers

Glycopeptide Synthesis: Selective C-terminal Deblocking and Peptide Chain Elongation of Glucosylserine Derivatives

Benzyloxycarbonyl-(Z-)serine 2-bromoethyl ester (3b) reacts with 2,3,4,6-tetra-O-benzoyl-α-D-glucopyranosyl bromide (14) to give the glucosylserine ester 15.After conversion into the corresponding 2-iodoethyl ester 23 the carboxylic group is deblocked selectively by reductive elimination using zinc.In this procedure the Z and the carbohydrate protective functions as well as the sensitive O-glycoside bond remain unaffected.The glycosylserine 24 is condensed with amino acid 2-bromoethyl esters 2 to form protected glycodipeptide 2-bromoethyl esters 18 which are extended to give glycotripeptide esters 25 after selective carboxyl deblocking.Whereas protected serine dipeptides 5 are glycosylated with 14 to form the conjugates 18, the glycosylation of the serine tripeptides 10 was not successful.